Harald Peeters
Overview
Explore the profile of Harald Peeters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holvoet T, Truyens M, De Galan C, Peeters H, Mesonero Gismero F, Elorza A, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256499
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of the current study was to assess the safety and effectiveness of...
2.
Geldof J, Truyens M, Hanssens M, Van Gucht E, Holvoet T, Elorza A, et al.
J Crohns Colitis
. 2024 Jan;
18(8):1202-1214.
PMID: 38243807
Background And Aims: No consensus exists on optimal strategy to prevent postoperative recurrence [POR] after ileocaecal resection [ICR] for Crohn's disease [CD]. We compared early medical prophylaxis versus expectant management...
3.
Vermeire S, Hanzel J, Lowenberg M, Ferrante M, Bossuyt P, Hoentjen F, et al.
J Crohns Colitis
. 2023 Nov;
18(4):540-547.
PMID: 37934813
Background And Aims: We explored the potential for differential efficacy of vedolizumab between early and late ulcerative colitis [UC] with evaluation of clinical, endoscopic, and histological endpoints. Methods: This was...
4.
Lemmens P, Louis E, van Moerkercke W, Pouillon L, Somers M, Peeters H, et al.
Clin Gastroenterol Hepatol
. 2023 Jul;
22(1):154-163.e3.
PMID: 37442318
Background & Aims: Several advanced therapies (biologic therapies and small molecules) have been approved for the treatment of moderate-to-severe ulcerative colitis. The registration trials for these agents typically excluded patients...
5.
Truyens M, Lobaton T, Ferrante M, Bossuyt P, Vermeire S, Pouillon L, et al.
Gastroenterology
. 2022 Aug;
163(5):1294-1305.e3.
PMID: 35940251
Background & Aims: Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD), and only limited treatment options are available. Based on the hypothetical link between low serum tryptophan...
6.
De Galan C, Truyens M, Peeters H, Mesonero Gismero F, Elorza A, Torres P, et al.
J Crohns Colitis
. 2022 Apr;
16(11):1676-1686.
PMID: 35442433
Background And Aims: Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal manifestations are limited. The aim here...
7.
De Galan C, Gonzales G, Van Welden S, Tavernier S, Lobaton T, van Moerkercke W, et al.
Clin Transl Med
. 2022 Apr;
12(4):e769.
PMID: 35384344
No abstract available.
8.
Bossuyt P, Pouillon L, Claeys S, DHaens S, Hoefkens E, Strubbe B, et al.
J Crohns Colitis
. 2021 Jul;
16(2):199-206.
PMID: 34297099
Background: With point of care testing [POCT] for infliximab [IFX], ultraproactive therapeutic drug monitoring [TDM] with ad-hoc dose optimisation is possible in patients with inflammatory bowel disease [IBD]. Aim: To...
9.
Allais L, Verschuere S, Maes T, De Smet R, Devriese S, Gonzales G, et al.
PLoS One
. 2020 Aug;
15(8):e0236657.
PMID: 32760089
Crohn's disease is a pathological condition of the gastro-intestinal tract, causing severe transmural inflammation in the ileum and/or colon. Cigarette smoking is one of the best known environmental risk factors...
10.
Somers M, Bossuyt P, Ferrante M, Peeters H, Baert F
J Crohns Colitis
. 2019 Dec;
14(5):680-685.
PMID: 31875891
The emergence of biosimilars is generally considered as an opportunity to guarantee accessibility to affordable treatments and to enhance financial sustainability of national health systems. Since 2017, five biosimilars of...